Tg Therapeutics (TGTX) Debt to Equity (2019 - 2025)
Historic Debt to Equity for Tg Therapeutics (TGTX) over the last 7 years, with Q3 2025 value amounting to $0.4.
- Tg Therapeutics' Debt to Equity fell 6820.13% to $0.4 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.4, marking a year-over-year decrease of 6820.13%. This contributed to the annual value of $1.1 for FY2024, which is 7622.05% up from last year.
- Per Tg Therapeutics' latest filing, its Debt to Equity stood at $0.4 for Q3 2025, which was down 6820.13% from $0.89 recorded in Q2 2025.
- Over the past 5 years, Tg Therapeutics' Debt to Equity peaked at $3.52 during Q1 2023, and registered a low of $0.05 during Q3 2021.
- For the 5-year period, Tg Therapeutics' Debt to Equity averaged around $0.86, with its median value being $0.62 (2023).
- As far as peak fluctuations go, Tg Therapeutics' Debt to Equity skyrocketed by 127844.14% in 2022, and later plummeted by 8200.97% in 2024.
- Tg Therapeutics' Debt to Equity (Quarter) stood at $0.29 in 2021, then surged by 324.93% to $1.21 in 2022, then tumbled by 48.63% to $0.62 in 2023, then soared by 76.22% to $1.1 in 2024, then tumbled by 63.24% to $0.4 in 2025.
- Its last three reported values are $0.4 in Q3 2025, $0.89 for Q2 2025, and $1.03 during Q1 2025.